ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$21 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4,933.7% |
| Net Income | -$20 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -5,451.7% |
| EPS Diluted | -2.56 | -0.46 | -0.73 | -1.31 |
| % Growth | -456.5% | 37% | 44.3% | – |
| Operating Cash Flow | -$1 | -$2 | -$2 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$2 | -$2 | -$0 |